Jump to content

Onyema Ogbuagu

Shí Wikipedia, njikotá édémédé nke onyobulạ
Onyema Ogbuagu
mmádu
ụdịekerenwoke Dezie
ụbọchị ọmụmụ ya1978 Dezie
ọrụ ọ na-arụresearcher Dezie

Onyema Eberechukwu Ogbuagu (amụrụ na June 20, 1978) bụ dọkịta na-efe efe, onye nkuzi, onye nchọpụta, na onye nchọpụta nyocha ahụike, onye a zụlitere ma gụọ akwụkwọ na Naijiria. Ọ bụ osote prọfesọ na Yale School of Medicine na New Haven, CT ma bụrụkwa onye nduzi nke Yale AIDS Program clinical trials unit.[1] Enyemaka nyocha ya lekwasịrị anya na mgbochi HIV / AIDS na ịgba ọgwụ mgbochi COVID-19 na ọgwụgwọ ọgwụgwọ.[2] Ọ gbanwere uche ya na mbido ọrịa COVID nke 2019 wee sonye dị ka onye isi nchọpụta (PI) na nnwale ọgwụ mgbochi COVID-19 nke Pfizer-BioNtech na nnwale Remdesivir SIMPLE na 2020 na 2021.[3][4][5] N'ịchụso akụkụ ahụike zuru ụwa ọnụ nke ọrụ ya, Ogbuagu na-akwadokwa mmemme agụmakwụkwọ ahụike nke ndị dọkịta na mba ndị na-enweta ego dị ala na ndị dị n'etiti na mpaghara Sahara Africa na Rwanda (2013-2018) na Liberia (2017 ruo ugbu a) yana mmemme ọgwụgwọ HIV na Liberia (2018 ruo ugbu a).

N'ọrụ ya dị ka onye nkuzi ahụike ọha na eze, ọ rụrụ ọrụ iji mụbaa nghọta ọha na eze banyere ọgwụ mgbochi mRNA.[6][7][8][9][10] Ogbuagu arụwokwa ọrụ iji belata mgbochi mgbochi.[11] Ọ bụ onye edemede na edemede 43 dị ka National Library of Medicine si kwuo.[12] Dị ka Google Scholar si kwuo, otu edemede o dere na Remdesivir na ojiji ya maka COVID nke pụtara na JAMA ka e depụtara ugboro 504.[13] A họpụtara Ogbuagu dị ka ọkà okwu mmalite maka klas Yale School of Medicine nke 2021.[14]

Mbido ndụ na agụmakwụkwọ

[dezie | dezie ebe o si]

Onyema Ogbuagu na nwanne ejima yiri ya, Chibuzo Ogbuagu nke Abụọ, bụ ndị a mụrụ Chibuzo na Stella Ogbuagu. Ụmụ akwụkwọ doctoral nke Naijiria na-aga Mahadum Yale na Mahadum Pennsylvania, n'otu n'otu, mgbe amụrụ ejima ha. Di na nwunye ahụ gụsịrị akwụkwọ na 1974 na Mahadum Naijiria, Nsukka, ebe Stella bụ onye na-ekwu okwu ikpeazụ.[15] Ezinụlọ ahụ laghachiri Naịjirịa mgbe Onyema na Chibuzo dị afọ ise.

Tupu ha ezumike nká n'oge na-adịbeghị anya, nna Onyema bụ osote onye isi nke Mahadum Abia State, Naịjirịa, nne ya bụkwa prọfesọ nke mmekọrịta mmadụ na ibe ya na onye bụbu osote onye nnọchi anya otu ụlọ ọrụ ahụ.[16]

Onyema Ogbuagu gara Auntie Margaret International Primary School na Calabar, wee nweta agụmakwụkwọ sekọndrị ya na Federal Government College, Okigwe, Imo State, Nigeria (1988 ruo 1994), gụsịrị akwụkwọ na 15. Ọ gụsịrị akwụkwọ na College of Medical Sciences, Mahadum Calabar, Nigeria na 2014. Ọ gụsịrị akwụkwọ n'ụlọ ọgwụ Ebonyi State University Teaching Hospital na Abakaliki, Nigeria. Ọ laghachiri na United States, ebe ọ na-arụ ọrụ na Elmhurst campus nke Icahn School of Medicine na Mount Sinai. Ogbuagu gụsịrị akwụkwọ na ebe obibi ya na Mount Sinai n'afọ 2010.[1]

Ogbuagu gụsịrị akwụkwọ na Yale School of Medicine n'afọ 2012 wee were ọnọdụ ngalaba dị ka osote prọfesọ n'otu afọ ahụ. Ugbu a, ọ bụ osote prọfesọ nke ọgwụ na Ngalaba Internal Medicine, Ngalaba nke Ọrịa Na-efe efe.[17]

Ndụ onwe onye

[dezie | dezie ebe o si]

Ogbuagu is married to Grace Igiraneza Ogbuagu.[18][19] She is a nephrologist and member of the International Nephrology Society.[20]

Ogbuagu bụ dọkịta HIV / AIDS ma na-eduzi mmemme nnwale ahụike na Yale nke na-eme nchọpụta banyere ọrịa na-efe efe. Ọ bụ onye isi nchọpụta na pharmacokinetic, nzọụkwụ 2 na 3 nchekwa na ịdị irè nke ihe ọhụrụ na-egbochi nje HIV na mgbakwunye na ọrụ ya na nso nso a na ọgwụ mgbochi COVID-19 na ọgwụgwọ.[21]

Ọ bụ dọkịta na Yale Medicine, ọrụ ahụike nke Yale School of Medicine, ma hụ ndị ọrịa na Yale New Haven Hospital's Nathan Smith Clinic.[22]

Ogbuagu na-azụ ndị dọkịta na Liberia na Rwanda. Ọ bụ prọfesọ nleta na Mahadum Mba nke Rwanda kemgbe afọ 2012, ebe ọ na-eduzi ndị ọrụ ahụike na ngalaba na-eto eto ma na-enyere ha aka n'ịrụ ọrụ nyocha ahụike ndị nwere mkpa dị ka HIV / AIDS na mgbochi antimicrobial. Na Liberia, ọ bụ onye nduzi mmemme nke Yale's Office of Global Health's mgbalị iji kwado ọzụzụ obibi Internal Medicine. Ọ zụrụ onye mbụ na-arịa ọrịa na Liberia.[23]

Nnyocha COVID-19 na HIV/AIDS

[dezie | dezie ebe o si]

Na mbido ọrịa COVID-19, Ogbuagu gbanwere uche ya site na nyocha AIDS / HIV na nlekọta ndị ọrịa iji duzie nnwale ọgwụ mgbochi maka COVID-19 na Yale Center for Clinical Investigation ebe ọ bụ PI na Pfizer-BioNtech COVID-19 mRNA na Yale na ndị okenye yana ọmụmụ ụmụaka maka ndị dị afọ 12-15 na ọnwa 6 ruo 11. Ọgwụ mgbochi Pfizer BioNtech toro eto natara ikike iji ya mee ihe mberede na United States site na Food and Drug Administration (FDA) na 2020 na nkwado FDA zuru ezu na 2021. E nwere ihe dịka saịtị 150 maka nnwale Pfizer BioNtech mRNA, nke ọ bụla na-eduga site na onye nchọpụta isi.

Ogbuagu bụkwa PI maka Phase 2b nke abụọ Sanofi-Glaxo Smith Klein novel COVID-19 vaccination candidate. Ọ bụkwa saịtị Yale PI maka ọmụmụ ọgwụgwọ COVID gụnyere ule Remdesivir SIMPLE nke dị nro na nke siri ike.[24]

Tupu ọrụ nnwale ahụike a, ọ nyochara ọgwụ, usoro 2 na 3 nke nchekwa na ịdị irè nke ihe ọhụrụ na-egbochi nje (HIV), ma mee nnwale mgbochi HIV.[1][25]

N'afọ 2015, a họpụtara Ogbuagu dị ka Fellow nke American College of Physicians. N'afọ 2017, ọ natara onyinye Steve Huot Faculty Award for Dedication and Excellence site na Yale School of Medicine's Internal Medicine Primary Care Program.

N'afọ 2014 na 2019, ọ natara ihe nrite Gerald H. Friedland maka ihe ngosi nyocha mba ụwa dị ịrịba ama site na Connecticut Infectious Diseases Society. Na Febụwarị 18, 2020, ọ natakwara onyinye site na Rwanda College of Physicians maka enyemaka ya na ọgụ megide ọrịa na-efe efe.

Akwụkwọ ndị e bipụtara

[dezie | dezie ebe o si]
  • Tuan J, Spichler-Moffarah A, Ogbuagu O. Nnyocha ọhụrụ SARS-CoV-2 nwere ọtụtụ ọnwa mgbe ọrịa COVID-19 siri ike gasịrị: ibute ọrịa ọzọ ma ọ bụ nje na-agbawa agbawa? BMJ Case Rep. 2021 Feb 4;14 (2):e240531. doi: 10.1136/bcr-2020-240531. PMID 33542020; PMCID: PMC8098910.
  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin, Jansen KU, Grini Trical Group C45 Cl. Nchebe na ịdị irè nke ọgwụ mgbochi COVID-19 BNT162b2 mRNA. N Engl J Med. 2020 Dec 31;383 (27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. PMID 33301246; PMCID: PMC7745181.
  • Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham CO, Ogbuagu O, Patel VV, Phillips KA, Tetrault JM, Shah M, Blackstock O. Nhọrọ maka mmejuputa mgbochi mgbochi HIV (PrEP): Nsonaazụ sitere na nyocha nke ndị na-ahụ maka nlekọta isi. Prev Med Rep. 2019 Oct 21;17:101012. doi: 10.1016/j.pmedr.2019.1012. PMID 31890474; PMCID: PMC6926349.
  • Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusigat, Cao H, Blair C, Wang H, Gaggar A, MJ, M, Ggani S-50. Mmetụta nke Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15;324 (11):1048-1057. doi: 10.1001/jama.2020.16349. PMID 32821939; PMCID: PMC7442954.
  • Ogbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, Almonte A, Wray T, Williams EC, Edelman EJ, Chan PA. Mgbasawanye na njikọ nke mmanya na-aba n'anya na iji ọgwụ ọjọọ eme ihe n'etiti ndị ikom na-enwe mmekọahụ na ndị ikom nyere ọgwụ HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS Behav 2019 Jan;23 (1):190-200. doi: 10.1007/s10461-018-2260-9. PMID 30145707; PMCID: PMC7020905.
  • Rutledge R, Madden L, Ogbuagu O, Meyer JP. Echiche nke ihe ize ndụ HIV na iru eru maka mgbochi tupu ikpughe onwe ya na ụmụ nwanyị na-etinye aka na usoro ikpe mpụ. AIDS Care 2018 Oct;30 (10):1282-1289. doi: 10.1080/09540121.2018.1447079. Epub 2018 Machị 11. PMID 29527934; PMCID: PMC6085161.
  • Kambutse I, Igiraneza G, Ogbuagu O. Echiche nke nje HIV na mgbochi tupu ikpughe ya n'etiti ndị ọrụ ahụike na ndị obodo na Rwanda. PLoS One. 2018 Nov 26;13 (11):e0207650. doi: 10.1371/journal.pone.020760 Erratum na: PLoS One 2019 Febụwarị 22;14 (2):e0212933. PMID 30475841; PMCID: PMC6261021.

Ihe odide

[dezie | dezie ebe o si]
  1. 1.0 1.1 1.2 Onyema Ogbuagu, MBBCh, FACP, FIDSA (en). medicine.yale.edu. Retrieved on 2021-06-17. Kpọpụta njehie: Invalid <ref> tag; name "oo" defined multiple times with different content
  2. Sopeyin (2020). "Transmission risk of respiratory viruses in natural and mechanical ventilation environments: Implications for SARS-CoV-2 transmission in Africa". BMJ Global Health 5 (8): e003522. DOI:10.1136/bmjgh-2020-003522. PMID 32863269. 
  3. Frenck (2021-07-15). "Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents". The New England Journal of Medicine 385 (3): 239–250. DOI:10.1056/NEJMoa2107456. ISSN 1533-4406. PMID 34043894. 
  4. Polack (2020-12-31). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". The New England Journal of Medicine 383 (27): 2603–2615. DOI:10.1056/NEJMoa2034577. ISSN 1533-4406. PMID 33301246. 
  5. Spinner (2020-09-15). "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial" (in en). JAMA 324 (11): 1048–1057. DOI:10.1001/jama.2020.16349. ISSN 0098-7484. PMID 32821939. 
  6. Julia Hollingsworth, Adam Renton, Emma Reynolds, Nada Bashir, Melissa Macaya and Meg Wagner (2020-12-10). Pfizer principal investigator "very optimistic" about positive news after FDA meeting (en). CNN. Retrieved on 2021-06-17.
  7. Video: What you need to know about COVID-19 vaccine distribution (en). ABC News. Retrieved on 2021-06-17.
  8. Low public trust could hurt vaccine distribution in minority communities (en). MSNBC.com. Retrieved on 2021-06-17.
  9. Johnson. "Large U.S. covid-19 vaccine trials are halfway enrolled, but lag on participant diversity", Washington Post, 27 August 2020. Retrieved on 2021-06-17.
  10. Connecticut's Shot in the Arm: State leaders, health officials discuss COVID-19 vaccine (en-US). WTNH.com (2020-12-02). Retrieved on 2021-08-30.
  11. COVID Vaccines and the Return to Life: Part 1 (en-US). The Aspen Institute. Retrieved on 2021-07-02.
  12. Onyema Ogbuagu - Search Results - PubMed (en). PubMed. Retrieved on 2021-06-23.
  13. Spinner (2020-09-15). "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial". JAMA 324 (11): 1048–1057. DOI:10.1001/jama.2020.16349. ISSN 0098-7484. PMID 32821939. 
  14. MD Class of 2021 Selects Associate Professor Onyema Ogbuagu as Commencement Speaker (en). medicine.yale.edu. Retrieved on 2021-06-17.
  15. "Meet Onyema Ogbuagu, di Nigerian inside Pfizer Covid-19 vaccine breakthrough", BBC News Pidgin. Retrieved on 2021-06-17.
  16. PROFILE: Meet Onyema Ogbuagu, UNICAL graduate leading COVID-19 vaccine research in US (en-US). TheCable (2020-11-22). Retrieved on 2022-02-02.
  17. Barakat (November 2018). "The Changing Face of HIV Care: Expanding HIV Training in an Internal Medicine Residency Program". Academic Medicine: Journal of the Association of American Medical Colleges 93 (11): 1673–1678. DOI:10.1097/ACM.0000000000002317. ISSN 1938-808X. PMID 29901657. 
  18. Yale physician, daughter share message about COVID vaccination as pediatric hospitalizations surge (en-US). WTNH.com (2022-01-08). Retrieved on 2022-02-03.
  19. Lucci-Canapari. Vaccine Clinic Offers Choice and Reassurance to New Haven Children (en). medicine.yale.edu. Retrieved on 2022-02-03.
  20. Parmar (2020-05-12). Research by Young ISN Members Highlights the Importance of Sub-tertiary Hospital Capacity to Manage Kidney Disease in Low- and Middle-income Countries (en-US). International Society of Nephrology. Retrieved on 2022-02-03.
  21. Horowitch (2020-04-06). Yale investigates potential treatments for COVID-19 (en). Yale Daily News. Retrieved on 2021-06-17.
  22. Onyema E. Ogbuagu, MD Infectious Disease of Yale New Haven Hospital. www.ynhh.org. Retrieved on 2022-02-02.
  23. Onyema Ogbuagu (en). Yale Medicine. Retrieved on 2021-06-17.
  24. Spinner (2020-09-15). "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial". JAMA 324 (11): 1048–1057. DOI:10.1001/jama.2020.16349. ISSN 1538-3598. PMID 32821939. 
  25. Nneji (April 29, 2021). COVID-19 Clinical Trials for Treatment and Prevention - Learning from Successes (en). Columbia Alumni Association of Fairfield County. Retrieved on 2022-02-02.